Classifications

• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
  • A01N37/06—Unsaturated carboxylic acids or thio analogues thereof; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
  • A01N37/10—Aromatic or araliphatic carboxylic acids, or thio analogues thereof; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N41/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom
  • A01N41/02—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom containing a sulfur-to-oxygen double bond
  • A01N41/04—Sulfonic acids; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
  • A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
  • C08J7/00—Chemical treatment or coating of shaped articles made of macromolecular substances
  • C08J7/04—Coating
• • C—CHEMISTRY; METALLURGY
  • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
  • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
  • C09K3/00—Materials not provided for elsewhere

Definitions

• the present invention relates to a virus infection prevention member.
• the highly pathogenic avian influenza virus has mutated and has been confirmed to infect humans, and there is also concern about the Sars virus, which has an extremely high mortality rate, and anxiety about the virus is only increasing.
• Patent Document 1 proposes an antiviral synthetic resin composition containing 0.5 parts by mass or more of a sulfonic acid surfactant per 100 parts by mass of the synthetic resin.
• the above-mentioned antiviral synthetic resin composition has a problem in that it does not exhibit sufficient antiviral properties (viral infection inhibiting effect) when used in a coating film.
• the present invention provides a virus infection prevention member that contains a virus infection inhibitor in a base material such as a coating film or a synthetic resin molded body, exhibits an excellent virus infection prevention effect, and can reduce viruses in a short time. do.
• the virus infection prevention member of the present invention is a virus infection prevention member comprising a base material and a virus infection inhibitor contained in the base material and exposed on the surface of the base material,
• the pH of the surface of the virus infection prevention member at 25° C. is 5.5 or less.
• the virus infection prevention member of the present invention exhibits an excellent virus infection prevention effect against both enveloped viruses and non-enveloped viruses, and can reduce various types of viruses in a short time.
• the virus infection inhibiting member of the present invention includes a base material and a virus infection inhibiting agent contained in the base material and exposed on the surface of the base material.
• the virus infection prevention member contains a base material.
• the base material is not particularly limited as long as it can contain the virus infection inhibiting agent described below and the pH of the surface of the virus infection inhibiting member at 25° C. can be 5.5 or less.
• a coating film examples include synthetic resin molded bodies.
• the synthetic resin constituting the coating film and the synthetic resin molded article is not particularly limited, and examples thereof include acrylic resins, polyolefin resins, and the like. Note that the synthetic resins may be used alone or in combination of two or more kinds.
• the acrylic resin is not particularly limited, and includes, for example, a homopolymer containing an acrylic monomer such as methyl (meth)acrylate, ethyl (meth)acrylate, butyl (meth)acrylate, or pentyl (meth)acrylate as a monomer unit; Examples include copolymers, copolymers containing as monomer units an acrylic monomer and one or more vinyl monomers copolymerizable with the acrylic monomer. Note that (meth)acrylate means acrylate or methacrylate.
• vinyl monomers that can be copolymerized with acrylic monomers include acrylonitrile, methacrylonitrile, maleic anhydride, and acrylamide.
• the polyolefin resin is not particularly limited, and examples thereof include polyethylene resin, polypropylene resin, and the like.
• the polyethylene resin is not particularly limited, and examples thereof include low density polyethylene, medium density polyethylene, high density polyethylene, linear low density polyethylene, and the like.
• the polypropylene resin is not particularly limited, and examples thereof include propylene homopolymers, copolymers of propylene and other olefins, and the like.
• the copolymer of propylene and other olefin may be any of a block copolymer, a random copolymer, and a random block copolymer.
• olefins copolymerized with propylene examples include ethylene, 1-butene, 1-pentene, 4-methyl-1-pentene, 1-hexene, 1-octene, 1-nonene, 1-decene, and other ⁇ -olefins. - Examples include olefins.
• the base material preferably has a reduced content of basic filler in order to improve the virus infection inhibiting effect of the virus infection inhibiting member. Specifically, it is preferably 0 to 10 parts by weight, more preferably 0 parts by weight (preferably not contained) based on 100 parts by weight of the synthetic resin constituting the base material.
• the basic filler include calcium carbonate, calcium oxide, zinc carbonate, zinc oxide, magnesium carbonate, magnesium oxide, magnesium hydroxide, aluminum hydroxide, and particulate alumina.
• the base material contains a virus infection inhibitor.
• the virus infection inhibiting agent contains a virus infection inhibiting compound as an active ingredient.
• the content of the virus infection inhibiting compound in the virus infection inhibitor is preferably 50% by mass or more, more preferably 60% by mass or more, more preferably 70% by mass or more, more preferably 80% by mass or more, and 90% by mass or more. is more preferable, more preferably 95% by mass or more, more preferably 95% by mass or more, more preferably 99% by mass or more, and more preferably 100% by mass.
• the content of the virus infection inhibiting compound in the virus infection inhibitor is preferably 50% by mass or more, more preferably 60% by mass or more, more preferably 70% by mass or more, more preferably 80% by mass or more, based on the active ingredients. More preferably 90% by mass or more, more preferably 95% by mass or more, more preferably 95% by mass or more, more preferably 99% by mass or more, and even more preferably 100% by mass.
• the virus infection inhibiting compound is not particularly limited, but preferably contains an anionic functional group or a salt thereof in the molecule since the virus infection inhibiting member exhibits an excellent virus infection inhibiting effect.
• the anionic functional group refers to a functional group that can generate anions by releasing cations. Examples of the cation include hydrogen ion H + , sodium ion Na + , potassium ion K + and the like.
• a virus infection inhibiting compound having an anionic functional group or a salt thereof in its molecule exhibits an excellent virus infection inhibiting effect due to the molecular structure portion containing the anionic functional group or its salt.
• a virus infection inhibiting compound having an anionic functional group or a salt thereof in the molecule has an excellent virus infection inhibiting effect, particularly against enveloped viruses.
• anionic functional group or its salt examples include, but are not limited to, carboxy groups (-COOH), carboxy group salts, sulfonic acid groups (sulfo groups, - At least one infection-inhibiting functional group selected from the group consisting of SO 3 H) and salts of sulfonic acid groups is preferred.
• Salts of carboxy groups are not particularly limited, and examples include potassium salts (-COOK), sodium salts (-COONa), calcium salts [(-COO - ) 2 Ca 2+ ], ammonium salts (-COO - NH 4 + ), magnesium salt [(-COO - ) 2 Mg 2+ ], barium salt [(-COO - ) 2 Ba 2+ ], and the like.
• Salts of sulfonic acid groups are not particularly limited, and include, for example, potassium salts (-SO 3 K), sodium salts (-SO 3 Na), calcium salts [(-SO 3 - ) 2 Ca 2+ ], ammonium salt (-SO 3 - NH 4 + ), magnesium salt [(-SO 3 - ) 2 Mg 2+ ], barium salt [(-SO 3 - ) 2 Ba 2+ ], etc.
• Sodium salts are preferred.
• the effect of inhibiting virus infection refers to the effect of eliminating or reducing the infectivity of a virus to cells, or preventing it from proliferating in cells even if infected.
• methods for confirming the presence or absence of virus infectivity include ISO 18184 and JIS L1922 for textile products, and ISO 21702 for products with plastics and non-porous surfaces other than textile products.
• Other methods include the plaque method and the hemagglutination titer (HAU) measurement method described in "Medical and Pharmaceutical Virology” (first edition published in April 1990).
• the virus infection inhibiting compound having a carboxy group only needs to have one or more carboxy groups in the molecule, and includes, for example, a polymer having a carboxy group in the side chain of a linear polymer, mellitic acid, aconitic acid, Citric acid, oxalic acid, malonic acid, succinic acid, glutaric acid, adipic acid, pimelic acid, suberic acid, fumaric acid, maleic acid, itaconic acid, citraconic acid, mesaconic acid, phthalic acid, isophthalic acid, terephthalic acid, methylene dichloride Salicylic acid, cis- ⁇ 4-tetrahydrophthalic acid, gluconic acid, mucinic acid, 3,3'-thiodipropionic acid, 2,2'-thiodiglycolic acid, 3,3'-dithiodipropionic acid, 2,2' -Dithiodiglycolic acid, 2,2'-dithi
• the linear polymer is not particularly limited, and for example, vinyl polymer, polyester, and polyurethane are preferable, and vinyl polymer is more preferable.
• Examples of the polymer having a carboxyl group in the side chain of a linear polymer include a polymer containing a carboxyl group-containing monomer containing a carboxyl group as a monomer unit.
• the polymer containing a carboxyl group-containing monomer as a monomer unit may be a homopolymer of the carboxyl group-containing monomer, or a copolymer of the carboxyl group-containing monomer and a monomer copolymerizable therewith.
• Carboxy group-containing monomers are not particularly limited, and examples include acrylic acid, methacrylic acid, ⁇ -carboxyethyl (meth)acrylate, 5-carboxypentyl (meth)acrylate, succinic acid mono(meth)acryloyloxyethyl ester, ⁇ -Carboxypolycaprolactone mono(meth)acrylate, crotonic acid, maleic acid, fumaric acid, itaconic acid, citraconic acid, carboxybetaine type monomers, etc., and acrylic acid and methacrylic acid are preferred.
• the carboxy group-containing monomers may be used alone or in combination of two or more types.
• a virus infection inhibiting compound containing a salt of a carboxy group only needs to have one or more salts of a carboxy group in the molecule, for example, a polymer having a salt of a carboxy group in the side chain of a linear polymer. , salts of mellitic acid, salts of aconitic acid, salts of citric acid, salts of oxalic acid, salts of malonic acid, salts of succinic acid, salts of glutaric acid, salts of adipic acid, salts of pimelic acid, salts of suberic acid.
• the linear polymer is not particularly limited, and for example, vinyl polymer, polyester, and polyurethane are preferable, and vinyl polymer is more preferable.
• Examples of the polymer having a salt of a carboxyl group in the side chain of a linear polymer include a polymer containing a salt of a carboxyl group-containing monomer as a monomer unit.
• the polymer containing a salt of a carboxyl group-containing monomer as a monomer unit may be a homopolymer of a salt of a carboxyl group-containing monomer, or a copolymer of a salt of a carboxyl group-containing monomer and a monomer copolymerizable therewith. It's okay.
• Examples of the salt of the carboxyl group-containing monomer include sodium salt, calcium salt, ammonium salt, magnesium salt, barium salt, etc., with sodium salt being preferred. Note that the carboxy group-containing monomer is the same as described above, so a description thereof will be omitted.
• Virus infection inhibiting compounds containing sulfonic acid groups only need to have one or more sulfonic acid groups in the molecule, such as polymers having sulfonic acid groups in the side chains of linear polymers, polystyrene sulfone, etc.
• the linear polymer is not particularly limited, and for example, vinyl polymer, polyester, and polyurethane are preferable, and vinyl polymer is more preferable.
• Examples of the polymer having a sulfonic acid group in the side chain of a linear polymer include a polymer containing a sulfonic acid group-containing monomer containing a sulfonic acid group as a monomer unit.
• polymers containing sulfonic acid group-containing monomers as monomer units include polymers containing styrene sulfonic acid units, homopolymers of styrene sulfonic acid, styrene-styrene sulfonic acid copolymers, and benzene rings of polystyrene.
• examples include compounds in which the benzene ring of a polymer containing a styrene component is sulfonated.
• the sulfonic acid group-containing monomer is not particularly limited, and examples thereof include p-styrenesulfonic acid, m-styrenesulfonic acid, o-styrenesulfonic acid, and the like.
• the virus infection inhibiting compound containing a salt of a sulfonic acid group may have one or more salts of a sulfonic acid group in its molecule, such as linear alkylbenzene sulfonate, ⁇ -olefin sulfonate, etc.
• alkyldiphenyl ether sulfonate polyoxyalkylene alkyl ether sulfate, lauryl sulfate, polymer having a sulfonic acid group salt in the side chain of a linear polymer, polystyrene sulfonic acid salt, formamidine sulfinic acid salt, Salts of 3-aminobenzenesulfonic acid, salts of hydroxybenzenesulfonic acid, salts of m-xylene-4-sulfonic acid, salts of 5-sulfosalicylic acid, salts of sulfanilic acid, 2-amino-3,5-dimethylbenzenesulfone Acid salts, 1,3-phenylenediamine-4-sulfonic acid salts, sulfonated (styrene-divinylbenzene copolymer) salts, carrageenan salts, sulfonated polyether sulfone salts, car
• linear alkylbenzenesulfonates include potassium dodecylbenzenesulfonate, sodium dodecylbenzenesulfonate, calcium dodecylbenzenesulfonate, ammonium dodecylbenzenesulfonate, magnesium dodecylbenzenesulfonate, barium dodecylbenzenesulfonate, and tridecylbenzene.
• Examples include potassium sulfonate, sodium tridecylbenzenesulfonate, ammonium tridecylbenzenesulfonate, potassium tetradecylbenzenesulfonate, sodium tetradecylbenzenesulfonate, ammonium tetradecylbenzenesulfonate, and sodium dodecylbenzenesulfonate is preferred. .
• Examples of the ⁇ -olefin sulfonate include C12 to C18 potassium olefin sulfonate, C12 to C18 sodium olefin sulfonate, C12 to C18 calcium olefin sulfonate, C12 to C18 ammonium olefin sulfonate, and C12 to C18 olefin sulfonate.
• C12 to C18 barium olefin sulfonate, and C14 sodium tetradecene sulfonate are preferred.
• alkyldiphenyl ether sulfonate examples include potassium salts, sodium salts, calcium salts, ammonium salts, magnesium salts, and barium salts of alkylphenyl ethers having an alkyl group of C6 to C18.
• the linear polymer is not particularly limited, and for example, vinyl polymer, polyester, and polyurethane are preferable, and vinyl polymer is more preferable.
• the polymer having a salt of a sulfonic acid group in the side chain of the linear polymer is not particularly limited, and includes, for example, a polymer containing a monomer containing a salt of a sulfonic acid group as a monomer unit. Can be mentioned.
• polymers containing sulfonic acid group salt-containing monomers as monomer units include, for example, polymers containing styrene sulfonate units, homopolymers of styrene sulfonate, and styrene-styrene sulfonic acid.
• examples include salt copolymers, sulfonates of compounds in which the benzene rings of polystyrene are sulfonated, and sulfonates of compounds in which the benzene rings of polymers containing a styrene component are sulfonated.
• the monomer containing a salt of a sulfonic acid group is not particularly limited, and examples thereof include potassium p-styrenesulfonate, potassium m-styrenesulfonate, potassium o-styrenesulfonate, sodium p-styrenesulfonate, and m-styrenesulfonic acid.
• Sodium styrene sulfonate is preferred, and sodium p-styrene sulfonate is more preferred because it has less steric hindrance in reactivity with viruses.
• the above-mentioned polymer having an anionic functional group or a salt thereof in the side chain of the linear polymer is composed of a monomer having the anionic functional group or a salt thereof (anionic functional group-containing monomer) and a monomer containing the anionic functional group. It may also be a copolymer of a monomer and a copolymerizable monomer.
• Monomers copolymerizable with the anionic functional group-containing monomer are not particularly limited, and include, for example, alkyl acrylate, alkyl methacrylate, vinyl alkyl ether, vinyl acetate, ethylene, propylene, butylene, butadiene, diisobutylene, vinyl chloride, and chloride.
• Examples include vinylidene, 2-vinylnaphthalene, styrene, acrylonitrile, acrylamide, methacrylamide, diacetone acrylamide, vinyltoluene, and vinylpyridine.
• the monomers copolymerizable with the anionic functional group-containing monomer may be used alone or in combination of two or more.
• the above polymer that becomes the virus infection inhibiting compound may be polymerized using a general-purpose polymerization method.
• a virus infection inhibiting compound can be obtained by polymerizing a monomer composition containing an anionic functional group-containing monomer in the presence of a general-purpose radical polymerization initiator.
• the radical polymerization initiator include thermally cleavable radical polymerization initiators such as 1-hydroxycyclohexane-1-ylphenyl ketone, t-hexyl peroxypivalate, benzoyl peroxide, and azobisisobutyronitrile. It will be done.
• the pKa1 at 25° C. of the virus infection inhibiting compound is preferably 5.0 or less, more preferably 4.7 or less. When the pKa1 at 25° C. of the virus infection inhibiting compound is 5.0 or less, the virus infection inhibiting effect of the virus infection inhibiting agent is improved.
• the pKa1 of the virus infection inhibiting compound at 25°C is preferably -3 or more, more preferably -2 or more. When the pKa1 at 25°C of the virus infection inhibiting compound is -3 or more, the surface of the virus infection inhibiting compound becomes in an appropriate charge state during the interaction between the virus infection inhibiting compound and the virus, and the virus is effectively captured. Viruses can be inactivated.
• the virus infection inhibiting compound is a polyvalent acid
• the virus infection inhibiting compound undergoes ionization in multiple stages
• pKa1 refers to pKa calculated based on the ionization constant of the first stage.
• the acid dissociation constant Ka is defined by formula (2)
• pKa is the common expression of the reciprocal of the acid dissociation constant Ka. Defined by logarithm (3).
• the pKa1 of the virus infection inhibiting compound at 25°C refers to the value measured by titration. Specifically, titration is performed at 25°C using a virus infection inhibiting compound and sodium hydroxide, and the pH at 25°C is measured at the half-equivalent point (the point at which half of the amount that completes neutralization is dropped). By doing so, pKa1 can be determined. In addition, when the virus infection inhibiting compound is a mixture, the pKa1 of the virus infection inhibiting compound at 25°C is the pKa1 of the entire virus infection inhibiting compound at 25°C.
• the pKa1 of the compound inhibiting virus infection has a salt of an anionic functional group such as a salt of a carboxy group or a salt of a sulfonic acid group.
• the anionic functional group eg, carboxy group, sulfonic acid group, etc.
• the pKa1 of the virus infection inhibiting compound is determined by the method described above.
• a virus infection inhibiting compound is mixed with a 1 mol% hydrochloric acid aqueous solution, and the salt of an anionic functional group contained in the virus infection inhibiting compound is converted to an anionic functional group.
• An example of this method is to convert all the components into anionic functional groups and then remove hydrochloric acid and water by a general-purpose method such as freeze-drying.
• the weight average molecular weight of the polymer is preferably 3,000 or more, more preferably 5,000 or more, more preferably 10,000 or more, and even more preferably 100,000 or more.
• the weight average molecular weight of the virus infection inhibiting compound is 3000 or more, the virus infection inhibiting compound can interact with the virus at multiple points on the surface of the virus infection inhibiting member, and the virus on the virus infection inhibiting member The infection prevention effect can be improved.
• the weight average molecular weight of the polymer contained in the virus infection inhibiting compound is preferably 1,000,000 or less, more preferably 950,000 or less, more preferably 900,000 or less, more preferably 850,000 or less, more preferably 800,000 or less, and more preferably 500,000 or less.
• the weight average molecular weight of the virus infection inhibiting compound is 1,000,000 or less, the aggregation of the virus infection inhibiting compound dissolved into contaminated liquid such as virus-containing droplets attached to the surface of the virus infection inhibiting member is suppressed, and the virus infection inhibiting compound is inhibited.
• the compound can interact with the virus at multiple points, and the virus infection inhibiting effect of the virus infection inhibiting member can be improved.
• the weight average molecular weight of the virus infection inhibiting compound is the weight average molecular weight of the whole virus infection inhibiting compound.
• the weight average molecular weight of the polymer is a value measured by GPC (gel permeation chromatography) in terms of polystyrene.
• the measurement can be performed using the following measuring device and measurement conditions.
• Gel permeation chromatograph Manufactured by Waters, product name “2690 Separations Model”
• Column Manufactured by Showa Denko, product name “GPC KF-806L”
• Detector Differential refractometer Sample flow rate: 1mL/min
• the molecular weight of the virus infection inhibiting compound is preferably 100 or more, preferably 120 or more, and more preferably 150 or more.
• the molecular weight of the virus infection inhibiting compound is preferably 300 or less, more preferably 250 or less, and even more preferably 200 or less.
• the virus infection inhibiting compound can improve interaction with the virus on the surface of the virus infection inhibiting member, improving the virus infection inhibiting effect of the virus infection inhibiting member. I can do it.
• the molecular weight of the virus infection inhibiting compound is 300 or less, the diffusivity of the virus infection inhibiting compound dissolved into contaminated liquid such as virus-containing droplets attached to the surface of the virus infection inhibiting member is improved, and the virus infection inhibiting compound is The virus can quickly interact with the virus, and the virus infection prevention effect of the virus infection prevention member can be improved.
• the pH of the virus infection inhibiting compound is preferably 0.5 or higher, more preferably 1 or higher, and even more preferably 2 or higher.
• the pH of the virus infection inhibiting compound is preferably 12 or less, more preferably 11 or less, more preferably 10 or less, more preferably 9 or less, more preferably 6 or less, more preferably 5 or less, more preferably 4.7 or less.
• the pH of the virus infection inhibiting compound is 0.5 or higher, the virus infection inhibiting effect of the virus infection inhibiting agent is improved.
• the pH of the virus infection inhibiting compound is 12 or less, the effect of inhibiting virus infection against non-enveloped viruses is improved. Note that the pH of the virus infection inhibiting compound refers to the pH value at 25° C.
• the mixed solution may be a saturated aqueous solution in which the entire amount of the virus infection inhibiting compound is dissolved in purified water, or a portion of the virus infection inhibiting compound is dissolved in purified water.
• the virus infection inhibiting compound is preferably formed into particles because it can improve the interaction with viruses on the surface of the base material and improve the virus infection inhibiting effect of the virus infection inhibiting member.
• the D90 particle diameter of the virus infection inhibiting compound is preferably 1 ⁇ m or more, more preferably 2 ⁇ m or more, preferably 2.5 ⁇ m or more, more preferably 3 ⁇ m or more, and even more preferably 3.5 ⁇ m or more.
• the D90 particle size of the virus infection inhibiting compound is preferably 50 ⁇ m or less, more preferably 25 ⁇ m or less, preferably 22 ⁇ m or less, more preferably 20 ⁇ m or less, more preferably 18 ⁇ m or less, more preferably 16 ⁇ m or less, more preferably 14 ⁇ m or less, More preferably, the thickness is 12 ⁇ m or less.
• the D90 particle size is 1 ⁇ m or more, the overall surface area of the virus infection inhibiting compound becomes small, the aggregation of the virus infection inhibiting agent is reduced, and the virus infection inhibiting compound and the virus easily interact with each other, thereby inhibiting virus infection.
• the virus infection prevention effect of the member is improved.
• the D90 particle size is 50 ⁇ m or less, it is possible to prevent the aggregation of the virus infection inhibiting agent and increase the surface area to facilitate contact with the virus, thereby improving the virus infection inhibiting effect of the virus infection inhibiting member.
• the D90 particle size of a virus infection inhibiting compound is the particle size at which the cumulative frequency (accumulation from particles with small particle size) in the volume-based particle size distribution determined by laser scattering method is 90% (90% cumulative particle size). diameter).
• the virus infection inhibiting compound can contain coarse particles. This reduces the risk of The virus infection inhibiting compound has an action point on its surface that interacts with the virus, but by adjusting the particle size of the virus infection inhibiting compound to the above range, the action point present on the surface of the virus infection inhibiting compound can be reduced. The amount of the virus is adjusted to give the virus infection inhibitor an excellent virus infection inhibiting effect.
• the D90 particle size of a virus infection inhibiting compound refers to the particle size (90% cumulative particle size) at which the cumulative frequency (accumulation from particles with small particle size) in the volume-based particle size distribution determined by the laser scattering method is 90%.
• the D90 particle diameter of the virus infection inhibiting compound is a value measured based on the entire virus infection inhibiting compound.
• the virus infection inhibitor contains a virus infection inhibiting compound as an active ingredient.
• the method for producing the virus infection inhibitor is not particularly limited, and the virus infection inhibitor can be produced by mixing the virus infection inhibitor compound with a compound to be added as needed in a conventional manner.
• the content of the virus infection inhibiting compound in the base material is preferably 0.1 parts by mass or more, more preferably 0.5 parts by mass or more, more preferably 1 part by mass or more, and 2 parts by mass based on 100 parts by mass of the base material. Part or more is more preferable.
• the content of the virus infection inhibiting compound in the base material is preferably 30 parts by mass or less, more preferably 20 parts by mass or less, more preferably 10 parts by mass or less, and more preferably 7 parts by mass or less, based on 100 parts by mass of the base material. preferable.
• the content of the virus infection inhibiting compound in the base material is 0.1 parts by mass or more, the virus infection inhibiting effect of the virus infection inhibiting member can be improved.
• the content of the virus infection inhibiting compound in the base material is 30 parts by mass or less, the aggregation of the virus infection inhibiting compound dissolved into contaminated liquid such as virus-containing droplets attached to the base material is suppressed, and virus infection is inhibited.
• the blocking compound can interact with the virus at multiple points, and the virus infection blocking effect of the virus infection blocking member can be improved. Furthermore, deterioration of the appearance of the virus infection prevention member over time can be reduced.
• the virus infection inhibiting member contains a virus infection inhibiting agent in the base material, and the virus infection inhibiting agent is exposed on the surface of the base material.
• the virus infection inhibitor exposed on the surface of the substrate can come into contact with the virus, capture the virus, and inactivate the virus.
• the pH at 25° C. on the surface of the virus infection prevention member is 5.5 or less, preferably 5.0 or less, and more preferably 4.9 or less.
• the pH at 25° C. on the surface of the virus infection prevention member is preferably 3.0 or higher, more preferably 4.5 or higher.
• the pH at 25°C on the surface of the virus infection prevention member By setting the pH at 25°C on the surface of the virus infection prevention member to 3.0 or more, the surface charge state of the virus becomes favorable for the interaction of the virus infection prevention compound with the virus, and the virus infection prevention member can improve the effectiveness of preventing viral infection. Furthermore, deterioration of the appearance of the virus infection inhibiting compound due to acid can be reduced.
• the pH at 25°C on the surface of the virus infection prevention member is measured as follows. 400 mg of ion-exchanged water is dropped onto the surface of the virus infection prevention member and left for 120 minutes. The pH at 25°C of the ion-exchanged water dropped onto the surface of the virus infection prevention member is measured, and this pH is taken as the pH at 25°C on the surface of the virus infection prevention member.
• the pH at 25°C on the surface of the virus infection prevention member can be adjusted by selecting the material that makes up the base material (for example, synthetic resin, etc.) or by incorporating an inorganic acid into the base material. .
• the inorganic acid is not particularly limited, and examples thereof include hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, and boric acid.
• the inorganic acids may be used alone or in combination of two or more kinds.
• virus infection inhibitor exposed on the surface of the base material of the virus infection prevention member is not covered by the base material and is in an exposed state.
• Virus infection inhibitors exhibit excellent virus infection prevention effects against various viruses in a short period of time through the action of virus infection prevention compounds, and exhibit excellent virus infection prevention effects against both enveloped and non-enveloped viruses. do.
• enveloped viruses examples include influenza viruses (e.g., type A, type B, etc.), rubella virus, Ebola virus, coronaviruses (e.g., SARS virus, new coronavirus (SARS-CoV-2)), measles virus, varicella virus, etc.
• Herpes zoster virus herpes simplex virus, mumps virus, arbovirus, respiratory syncytial virus, hepatitis virus (e.g., hepatitis B virus, hepatitis C virus, etc.), yellow fever virus, AIDS virus, rabies virus, hantavirus, dengue virus, Nipah virus , lyssavirus, etc.
• non-enveloped viruses examples include feline calicivirus, adenovirus, norovirus, rotavirus, human papillomavirus, poliovirus, enterovirus, coxsackievirus, human parvovirus, encephalomyocarditis virus, and rhinovirus.
• the method for producing the virus infection prevention member is not particularly limited.
• a method of laminating and integrating a virus infection prevention member on the surface of a treated body (2) a method of preparing a raw material composition by incorporating a virus infection prevention agent into a raw material such as a synthetic resin, and extrusion molding or injection molding of this raw material composition.
• Examples include a method of manufacturing a virus infection inhibiting member having a desired shape by molding by a known molding method such as molding and containing a virus infection inhibiting agent in the raw material.
• a coating film formed by solidifying the paint serves as a base material, and a virus infection inhibitor is contained in this base material in an exposed state on the surface of the coating film to form a virus infection inhibiting member. is configured.
• the molded product obtained by molding raw materials such as synthetic resin is the virus infection prevention member, and the virus infection inhibitor is contained in an exposed state on the surface of the molded product. .
• the object to be treated is coated with a paint containing a virus infection inhibitor
• the molded article molded in the manufacturing method of (2) above is one that is desired to have a virus infection inhibiting effect.
• examples include, but are not limited to, wallpaper, decorative sheets, flooring materials, textile products (woven fabrics, non-woven fabrics, knitted fabrics), interior goods and interior materials (sheets) for vehicles (e.g. cars, airplanes, ships, etc.). , child seats and the foam materials that make up these), kitchen products, baby products, architectural interior materials, etc.
• paints conventionally known paints are used, such as oil-based paints (for example, blended paints, oil varnishes, etc.), cellulose paints, synthetic resin paints, and the like. Paints also include photocurable paints that polymerize to produce a binder component when irradiated with radiation such as ultraviolet rays.
• oil-based paints for example, blended paints, oil varnishes, etc.
• cellulose paints for example, blended paints, oil varnishes, etc.
• Paints also include photocurable paints that polymerize to produce a binder component when irradiated with radiation such as ultraviolet rays.
• the paint may contain additives such as pigments, plasticizers, curing agents, extenders, fillers, anti-aging agents, thickeners, and surfactants within the range that does not impair its physical properties.
• additives such as pigments, plasticizers, curing agents, extenders, fillers, anti-aging agents, thickeners, and surfactants within the range that does not impair its physical properties.
• a method of incorporating the virus infection inhibitor into the paint for example, a method of supplying the virus infection inhibitor and the paint to a dispersion device and uniformly mixing them can be mentioned.
• the dispersion device include a high-speed mill, a ball mill, and a sand mill.
• Architectural interior materials are not particularly limited, and include, for example, flooring materials, wallpaper, ceiling materials, paints, doorknobs, switches, switch covers, wax, and the like.
• Vehicle interior supplies and vehicle interior materials are not particularly limited, and include, for example, seats, child seats, seat belts, car mats, seat covers, doors, ceiling materials, floor mats, door trims, instrument panels, consoles, glove boxes, hanging leather, handrails, etc. can be mentioned.
• the effect of inhibiting virus infection refers to the effect of eliminating or reducing the ability of viruses to infect cells, or preventing them from proliferating in cells even if infected.
• the virus infection inhibiting effect can be measured as follows.
• a square test piece with a side of 5.0 cm is cut out from the part where the virus infection prevention agent is exposed from the surface of the base material.
• a nonwoven fabric in the shape of a square plane with sides of 10 cm (for example, a nonwoven fabric commercially available from Nippon Paper Crecia Co., Ltd. under the trade name "Kimwipe S-200") is impregnated with 1 mL of water. Wipe the surface of the test piece with a non-woven cloth by moving it back and forth 10 times.
• a square blank piece with a side of 5.0 cm is cut out from a blank member having the same configuration except that the viral infection inhibiting member does not contain a virus infection inhibiting agent.
• the virus infectivity titer common logarithm value (common logarithm value) (PFU/cm 2 ) is calculated in the same manner as above.
• the antiviral activity value after 10 minutes from the start of the reaction in an antiviral test based on ISO 21702 is preferably 2.0 or more.
• the antiviral activity value after 24 hours from the start of the reaction in the antiviral test based on SO21702 is preferably 2.0 or more. Regardless of the type of virus to be evaluated, it is preferable that the antiviral activity value is 2.0 or more for at least one virus.
• acrylic polymer particles A and B As particles of the virus infection inhibiting compound, acrylic polymer particles A and B, phthalic acid particles, fumaric acid particles, hydroxybenzenesulfonic acid hydrate particles, m-xylene-4-sulfonic acid hydrate particles , 2-amino-3,5-dimethylbenzenesulfonic acid particles, polystyrene sodium sulfonate (PSSNa) particles, terephthalic acid particles, diethylenetriaminepentaacetic acid particles, triglycolamic acid particles, isophthalic acid particles, adipine Acid particles, citric acid particles, cis- ⁇ 4-tetrahydrophthalic acid (cis-4-Cyclohexene-1,2-dicarboxylic acid) particles, methylenedisalicylic acid (5,5'-methylenedisalicylic acid, 3,5') - particles of benzylic acid, particles of isophthalic acid, particles of sodium dodecylbenzenesulfon
• the raw material composition was coated onto a polyethylene film using a wire bar coater #14 to form a coating layer with a thickness of 35 ⁇ m.
• Radical polymerization was performed by irradiating the coating layer with ultraviolet rays with a wavelength of 365 nm at 25°C using a UV conveyor device (manufactured by Eye Graphics, product name "ECS301G1") so that the cumulative amount of light was 2000 mJ/ cm2 .
• Acrylic polymers (polymer having a carboxy group in the side chain of a linear polymer) A and B were obtained as virus infection inhibiting compounds.
• the virus infection inhibiting compound was coarsely pulverized using a roll press machine (Seishin Enterprise Co., Ltd., trade name "Model 150") under operating conditions of a rotation speed of 25 rpm and a pushing force of 25 t, and then crushed using a jet mill machine (manufactured by Nisshin Engineering Co., Ltd., trade name "150 type”) under operating conditions of 25 rpm and a pushing force of 25 tons. Particles of the virus infection inhibiting compound (acrylic polymer particles A and B) was obtained.
• sodium polystyrene sulfonate (PSSNa) particles As a virus infection inhibiting compound, sodium polystyrene sulfonate (manufactured by Nouryon Co., Ltd., trade name "Versa-TL 502", weight average molecular weight: 1,000,000) was applied at a rotation speed of 25 rpm using a roll press machine (Seishin Enterprise Co., Ltd., trade name "150 type").
• Tables 2 and 3 show the D90 particle diameter of the particles of the virus infection inhibiting compound.
• Tables 2 and 3 show the pKa1 at 25°C, pH at 25°C (compound pH), and molecular weight (weight average molecular weight in the case of polymer) of the virus infection inhibiting compound constituting the particles of the virus infection inhibiting compound. Ta.
• Examples 1 to 7, 13 to 16, 20 and 21, Comparative Example 1 A virus infection inhibitor containing 5 parts by mass of particles of the above-mentioned virus infection inhibiting compound shown in Table 2 and 95 parts by mass of an ultraviolet curable acrylic paint (trade name "AI-N2" manufactured by Coattec Co., Ltd.) were mixed. A coating composition was prepared. The coating composition was applied onto a polyethylene film to a thickness of 18 ⁇ m using a wire bar coater #8 to form a coating layer.
• the UV-curable acrylic paint was cured by irradiating the coating layer with ultraviolet rays with a wavelength of 365 nm at a cumulative light intensity of 500 mJ/cm 2 at 25°C using a UV conveyor device (“ECS301G1” manufactured by Eye Graphics). A coating film having a thickness of 18 ⁇ m was formed.
• a virus infection prevention member was formed on the polyethylene film, including a coating film containing an acrylic resin as a base material and a virus infection inhibitor contained in this coating film. A portion of the virus infection inhibiting agent (particles of the virus infection inhibiting compound) is exposed on the surface of the paint film, and the portion of the virus infection inhibiting compound particles exposed on the surface of the paint film is not covered by the paint film. Ta.
• Example 8 A coating film was formed in the same manner as in Example 1, except that a virus infection inhibitor containing 95 parts by mass of acrylic polymer particles A and 5 parts by mass of polystyrene sodium sulfonate (PSSNa) particles was used.
• a virus infection inhibitor containing 95 parts by mass of acrylic polymer particles A and 5 parts by mass of polystyrene sodium sulfonate (PSSNa) particles was used.
• a virus infection prevention member was formed on the polyethylene film, including a coating film containing an acrylic resin as a base material and a virus infection inhibitor contained in this coating film. A portion of the virus infection inhibiting agent (particles of the virus infection inhibiting compound) is exposed on the surface of the paint film, and the portion of the virus infection inhibiting compound particles exposed on the surface of the paint film is not covered by the paint film. Ta.
• Example 9 A coating film was formed in the same manner as in Example 1, except that a virus infection inhibitor containing 95 parts by mass of acrylic polymer particles B and 5 parts by mass of polystyrene sodium sulfonate (PSSNa) particles was used.
• a virus infection inhibitor containing 95 parts by mass of acrylic polymer particles B and 5 parts by mass of polystyrene sodium sulfonate (PSSNa) particles was used.
• a virus infection prevention member was formed on the polyethylene film, including a coating film containing an acrylic resin as a base material and a virus infection inhibitor contained in this coating film. A portion of the virus infection inhibiting agent (particles of the virus infection inhibiting compound) is exposed on the surface of the paint film, and the portion of the virus infection inhibiting compound particles exposed on the surface of the paint film is not covered by the paint film. Ta.
• Example 10 A resin composition was prepared by heating and mixing a virus infection inhibitor containing 5 parts by mass of acrylic polymer particles B and 95 parts by mass of polypropylene (PP, trade name "J707EG” manufactured by Prime Polymer Co., Ltd.) at 180°C. Next, the resin composition is heated to 180°C to make it into a molten state, and the resin composition is fed into a heat press machine whose temperature is adjusted to 180°C and formed into a sheet to form a polypropylene sheet with a thickness of 1.0 mm. Created.
• PP trade name "J707EG” manufactured by Prime Polymer Co., Ltd.
• a virus infection inhibiting member was obtained that included a sheet containing polypropylene as a base material and a virus infection inhibiting agent contained in this sheet. A portion of the virus infection inhibiting agent (particles of the virus infection inhibiting compound) was exposed on the surface of the sheet, and the portion of the virus infection inhibiting compound particles exposed on the sheet surface was not covered with polypropylene.
• Example 11 A resin composition was prepared by heating and mixing a virus infection inhibitor containing 5 parts by mass of acrylic polymer particles B with 95 parts by mass of polyethylene (PE, trade name "2208" manufactured by Prime Polymer Co., Ltd.) at 150°C. Next, the resin composition was heated to 150°C to make it into a molten state, and the resin composition was fed into a heat press machine whose temperature was adjusted to 180°C and formed into a sheet to form a polyethylene sheet with a thickness of 1.0 mm. Created.
• PE trade name "2208” manufactured by Prime Polymer Co., Ltd.
• a virus infection inhibiting member was obtained that included a sheet containing polyethylene as a base material and a virus infection inhibiting agent contained in this sheet. A portion of the virus infection inhibiting agent (particles of the virus infection inhibiting compound) was exposed on the surface of the sheet, and the portion of the virus infection inhibiting compound particles exposed on the sheet surface was not covered with polyethylene.
• Example 12 A coating film was formed in the same manner as in Example 1, except that a virus infection inhibitor containing 95 parts by mass of fumaric acid particles and 5 parts by mass of polystyrene sodium sulfonate (PSSNa) particles was used.
• a virus infection inhibitor containing 95 parts by mass of fumaric acid particles and 5 parts by mass of polystyrene sodium sulfonate (PSSNa) particles was used.
• a virus infection prevention member was formed on the polyethylene film, including a coating film containing an acrylic resin as a base material and a virus infection inhibitor contained in this coating film. A portion of the virus infection inhibiting agent (particles of the virus infection inhibiting compound) is exposed on the surface of the paint film, and the portion of the virus infection inhibiting compound particles exposed on the surface of the paint film is not covered by the paint film. Ta.
• Example 17 A virus infection inhibitor containing 5 parts by mass of isophthalic acid particles, 63 parts by mass of the main ingredient for urethane resin paint (trade name "Eco-Lock Grand Clear” manufactured by Rock Paint Co., Ltd.), and a curing agent for urethane resin paint (Rock Paint)
• a paint composition was prepared by mixing 32 parts by mass of a thinner (manufactured by Rock Paint Co., Ltd. under the trade name "Panalock Thinner Standard Type") and 30 parts by mass of thinner (manufactured by Rock Paint Co., Ltd. under the trade name "Panalock Thinner Standard Type”).
• the coating composition was applied onto a polyethylene film using a wire bar coater #10 to form a coating layer.
• the coating layer was dried at 60° C. for 1 hour and then cured at 25° C. for 48 hours to form a coating film with a thickness of 18 ⁇ m.
• a virus infection prevention member was formed on the polyethylene film, including a coating film containing a urethane resin as a base material and a virus infection inhibitor contained in this coating film. A portion of the virus infection inhibiting agent (particles of the virus infection inhibiting compound) is exposed on the surface of the paint film, and the portion of the virus infection inhibiting compound particles exposed on the surface of the paint film is not covered by the paint film. Ta.
• Example 18 A coating film was formed in the same manner as in Example 1, except that a virus infection inhibitor containing 95 parts by mass of isophthalic acid particles and 5 parts by mass of polystyrene sodium sulfonate (PSSNa) particles was used.
• a virus infection inhibitor containing 95 parts by mass of isophthalic acid particles and 5 parts by mass of polystyrene sodium sulfonate (PSSNa) particles was used.
• a virus infection prevention member was formed on the polyethylene film, including a coating film containing an acrylic resin as a base material and a virus infection inhibitor contained in this coating film. A portion of the virus infection inhibiting agent (particles of the virus infection inhibiting compound) is exposed on the surface of the paint film, and the portion of the virus infection inhibiting compound particles exposed on the surface of the paint film is not covered by the paint film. Ta.
• Example 19 A coating film was formed in the same manner as in Example 1, except that a virus infection inhibitor containing 95 parts by mass of isophthalic acid particles and 5 parts by mass of sodium dodecylbenzenesulfonate (DBSNa) particles was used.
• DBSNa sodium dodecylbenzenesulfonate
• a virus infection prevention member was formed on the polyethylene film, including a coating film containing an acrylic resin as a base material and a virus infection inhibitor contained in this coating film. A portion of the virus infection inhibiting agent (particles of the virus infection inhibiting compound) is exposed on the surface of the paint film, and the portion of the virus infection inhibiting compound particles exposed on the surface of the paint film is not covered by the paint film. Ta.
• Example 22-24 and 26 A polypropylene sheet having a thickness of 1.0 mm was produced in the same manner as in Example 10, except that a virus infection inhibitor containing 5 parts by mass of particles of the above-mentioned virus infection inhibiting compound shown in Table 3 was used.
• a virus infection inhibiting member was obtained that included a sheet containing polypropylene as a base material and a virus infection inhibiting agent contained in this sheet. A portion of the virus infection inhibiting agent (particles of the virus infection inhibiting compound) was exposed on the surface of the sheet, and the portion of the virus infection inhibiting compound particles exposed on the sheet surface was not covered with polypropylene.
• Example 25 A polyethylene sheet having a thickness of 1.0 mm was produced in the same manner as in Example 11, except that a virus infection inhibitor containing 5 parts by mass of particles of the above-mentioned virus infection inhibiting compound shown in Table 3 was used.
• a virus infection inhibiting member was obtained that included a sheet containing polyethylene as a base material and a virus infection inhibiting agent contained in this sheet. A portion of the virus infection inhibiting agent (particles of the virus infection inhibiting compound) was exposed on the surface of the sheet, and the portion of the virus infection inhibiting compound particles exposed on the sheet surface was not covered with polyethylene.
• the pH at 25° C. of the surface of the obtained virus infection prevention member was measured as follows, and the results are shown in the “Surface pH” column of Tables 2 and 3.
• the pH at 25° C. on the surface of the virus infection prevention member was measured as follows.
• the virus infection prevention member was placed in an atmosphere at 25°C.
• the surface of the virus infection prevention member was maintained at 25°C.
• 400 mg of ion-exchanged water at 25° C. was dropped onto the surface of this virus infection prevention member and left for 120 minutes.
• the pH of the ion-exchanged water dropped onto the surface of the virus infection prevention member at 25°C was measured, and this pH was taken as the pH at 25°C of the surface of the virus infection prevention member.
• the obtained virus infection prevention member was subjected to an antiviral test using influenza virus (enveloped virus) and feline calicivirus (non-enveloped virus), and the results are shown in Tables 2 and 3.
• test piece was prepared by cutting out a planar square shape with one side of 5.0 cm.
• the surface of the coating film of the obtained test piece was soaked in 1 mL of water with a square non-woven fabric (manufactured by Nippon Paper Crecia Co., Ltd., product name "Kimwipe S-200") with a side of 10 cm, and the surface of the coating film was covered with the non-woven fabric for 10 minutes. It was wiped back and forth and used as a test coating.
• a square non-woven fabric manufactured by Nippon Paper Crecia Co., Ltd., product name "Kimwipe S-200"
• test coating was subjected to an antiviral test against influenza virus and feline calicivirus in accordance with ISO21702.
• the virus infectivity of the test coating was calculated using the plaque method for the virus suspension 10 minutes and 24 hours after the reaction.
• a blank coating film was prepared in the same manner as above except that no virus infection inhibitor was contained, and based on this blank coating, the virus infection titer (common logarithm value) (PFU/cm 2 ) was determined in the same manner as above. was calculated.
• the virus infectivity titer (common logarithmic value) of the blank coating film was 6.5 PFU/cm 2 .
• the antiviral activity value was calculated by subtracting the virus infection value of the test coating from the virus infection value of the blank paint.
• the antiviral activity values are shown in Tables 2 and 3.
• the virus infection prevention member of the present invention can be applied to paint films, wallpapers, decorative sheets, flooring materials, textile products, interior products and interior materials for vehicles, kitchen products, baby products, architectural interior materials, etc.
• the virus infection prevention member of the present invention exhibits an excellent virus infection prevention effect against both enveloped viruses and non-enveloped viruses, and can reduce various types of viruses in a short time.

Landscapes

• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Chemical & Material Sciences (AREA)
• Pest Control & Pesticides (AREA)
• Environmental Sciences (AREA)
• Health & Medical Sciences (AREA)
• Zoology (AREA)
• Wood Science & Technology (AREA)
• Plant Pathology (AREA)
• Agronomy & Crop Science (AREA)
• Dentistry (AREA)
• General Health & Medical Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Polymers & Plastics (AREA)
• Medicinal Chemistry (AREA)
• Materials Engineering (AREA)
• Agricultural Chemicals And Associated Chemicals (AREA)
• Laminated Bodies (AREA)

Priority Applications (2)

Applications Claiming Priority (2)

Publications (1)

Family

ID=87935015

Family Applications (1)

Country Status (4)

Citations (10)

• 2023
  • 2023-03-03 WO PCT/JP2023/007991 patent/WO2023171557A1/ja not_active Ceased
  • 2023-03-03 JP JP2023519390A patent/JP7788051B2/ja active Active
  • 2023-03-03 CN CN202380015684.XA patent/CN118450802A/zh active Pending
  • 2023-03-08 TW TW112108500A patent/TW202348139A/zh unknown

Patent Citations (10)

Also Published As

Similar Documents

Legal Events